TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04715698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG-guided drug selection
Description: anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: empirical drug selection
Description: anti-hypertensive drug selection based on physician's experience only
Study: NCT01238328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning regimen
Description: For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GVHD) prophylaxis
Description: * Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical
Study: NCT00992823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron supplementation
Description: 40 doses of 30 mg of ferrous sulfate during a 10-month intervention period

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: iron supplementation
Description: supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
Study: NCT01622777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg daily of oral rosuvastatin for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
Study: NCT03245983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire and interview
Description: Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
Study: NCT01554800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-501
Description: A single dose infusion
Study: NCT04499222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portex
Description: nasotracheal intubation with PORTEX POLAR \[Smiths Medical International, Hythe, United Kingdom\] nasotracheal tube.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt
Description: nasotracheal intubation with Mallinckrodt TaperGuard \[Covidien, Ireland\] nasotracheal tube.
Study: NCT02447978

Intervention type: BIOLOGICAL
Intervention: Infanrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.

Intervention type: BIOLOGICAL
Intervention: Infanrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.

Intervention type: BIOLOGICAL
Intervention: Infanrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.

Intervention type: BIOLOGICAL
Intervention: Pediarix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).

Intervention type: BIOLOGICAL
Intervention: Pediarix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).

Intervention type: BIOLOGICAL
Intervention: Pediarix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).

Intervention type: BIOLOGICAL
Intervention: Kinrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine

Intervention type: BIOLOGICAL
Intervention: Kinrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine

Intervention type: BIOLOGICAL
Intervention: Kinrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
Study: NCT02202538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego
Description: Indego
Study: NCT02600091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
Study: NCT00328861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) Lymphocytes
Description: Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) Lymphocytes
Description: Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.
Study: NCT01819350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1, G2 and G3
Description: Nutritional, respiratory and endocrine group applicated 12 subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G4 and G5
Description: Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
Study: NCT04294147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab
Description: Administered SC
Study: NCT04271033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm.
Study: NCT03252223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone
Description: A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone
Description: A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
Study: NCT01887353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Patients will take ranolazine 1000 mg tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
Study: NCT04275024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Description: The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSORI-CM01 Granule
Description: PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
Study: NCT02255942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate and Zinc Oxide
Description: Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
Study: NCT01622387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass (CABG) surgery using a radial arterial conduit
Description: Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass surgery using a long saphenous vein conduit
Description: Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
Study: NCT02220712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-14597 IMD
Description: Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
Study: NCT02255942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Rice fortified with Ferrous Sulfate (ZnSO4)
Study: NCT03796351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10107
Description: Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner.
Study: NCT02255942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate and Zinc Sulfate
Description: Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
Study: NCT00604890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: API 31510 3% Topical Cream
Description: Topical treatment 3% active cream applied to the lesion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: API 31510 3% Topical Cream
Description: Topical treatment 3% active cream applied to the lesion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: API 31510 1.5% Topical Cream
Description: Topical treatment 1.5% active cream applied to the lesion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical treatment placebo applied to the lesion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical treatment placebo applied to the lesion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical treatment placebo applied to the lesion
Study: NCT03287362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: schema therapy
Description: The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: individualized supportive therapy
Description: The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
Study: NCT01881568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
Study: NCT02820025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxapram

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT01915979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone cronodose (Bethametasone)
Study: NCT03954262

Intervention type: BEHAVIORAL
Intervention: observation of propofol ANS response
Description: received an induction bolus or TCI infusion of propofol

Intervention type: BEHAVIORAL
Intervention: observation of propofol ANS response
Description: received an induction bolus or TCI infusion of propofol
Study: NCT00061932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Given IV
Study: NCT02656407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device
Description: Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
Study: NCT02255942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate
Description: Rice fortified with Ferric Pyrophosphate
Study: NCT02779166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Received 400mg celecoxib prior to surgery
Study: NCT00745433

Intervention type: DRUG
Intervention: repaglinide
Description: Start dose and frequency at the discretion of the physician following clinical practice

Intervention type: DRUG
Intervention: metformin
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study: NCT03262441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 500Mg Tab
Description: 500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
Study: NCT04000074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic Services
Description: Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Services
Description: Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
Study: NCT04559048

Intervention type: DRUG
Intervention: FK506
Description: FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
Study: NCT02090517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Dye Laser
Description: Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Pulsed Alexandrite Laser
Description: Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Dye Laser Plus Nd:YAG Laser
Description: The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodesiccation
Description: A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
Study: NCT01023646

Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate + Protein
Description: Light Tuna Packed in water.

Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate + Fat
Description: Butter

Intervention type: OTHER
Group type: OTHER
Intervention: Fiber
Description: Unrefined Carbohydrate

Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate load
Description: Carbohydrate
Study: NCT04666194

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold forceps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot snare
Study: NCT05281146

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chickpeas and crushed peanuts fortified biscuit
Description: This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
Study: NCT02598388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL IM injection of (1x10\*8 infectious units).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL IM injection of (1x10\*8 infectious units).
Study: NCT05281146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive stimulation for the mothers
Description: I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive stimulation for the mothers
Description: I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive stimulation for students
Description: * Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive stimulation for students
Description: * Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving